Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296

Biochemistry
M KovalenkoF D Böhmer

Abstract

The mechanism of action of AG1296, a potent and specific inhibitor of the platelet-derived growth factor (PDGF) receptor tyrosine kinase [Kovalenko, M., Gazit, A., Böhmer, A., Rorsman, Ch., Rönnstrand, L., Heldin, C.-H., Waltenberger, J., Böhmer, F. D., & Levitzki, A. (1994) Cancer Res. 54, 6106-6114] was investigated. This quinoxalin-type tyrphostin neither interferes with PDGF-BB binding to the PDGF beta-receptor nor has any effect on receptor dimerization. Kinetic analysis of the inhibition was carried out using a synthetic peptide substrate (KY751) corresponding to the sequence around tyrosine 751 autophosphorylation site of the PDGF receptor. It revealed purely competitive inhibition vis-à-vis ATP, mixed competitive inhibition vis-a-vis the peptide substrate for the non-activated receptor, and mixed competitive inhibition vis-à-vis both substrates for the activated receptor. Thus, the type of inhibition apparently changes upon receptor activation, indicating conformational changes at the ATP-binding site. The high degree of selectivity for the tyrphostin AG1296 might result from the complex type of interaction with the active center of the receptor as revealed by the kinetic analysis. Dose-response curves for inhibition of...Continue Reading

References

Apr 1, 1991·The American Journal of Physiology·G E BilderA B Schreiber
Nov 4, 1991·The American Journal of Cardiology·B CercekJ S Forrester
Nov 1, 1994·European Journal of Biochemistry·N Osherov, A Levitzki
Jan 17, 1995·International Journal of Cancer. Journal International Du Cancer·A GuhaC D Stiles
Jan 1, 1996·Breast Cancer Research and Treatment·A E WakelingJ R Woodburn

❮ Previous
Next ❯

Citations

Aug 24, 1999·Pharmacology & Therapeutics·A Levitzki
Jan 17, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alexander Levitzki
Apr 3, 2003·Bioorganic & Medicinal Chemistry·Aviv GazitAlexander Levitzki
Feb 13, 2008·Proceedings of the National Academy of Sciences of the United States of America·Robert E BolcomeJoanne Chan
Jan 30, 2002·Antioxidants & Redox Signaling·S WisemanA Rietveld
Jun 8, 2006·Annual Review of Biochemistry·Alexander Levitzki, Eyal Mishani
Oct 10, 2012·Annual Review of Pharmacology and Toxicology·Alexander Levitzki
Aug 13, 2008·The Journal of Cell Biology·Laurence VeraciniChristine Benistant
Feb 28, 2003·FEBS Letters·Rotem KarniAlexander Levitzki
Jan 21, 2016·Oncology Letters·Hongwei LiXianhou Yuan
Jul 23, 2013·Nanomedicine : Nanotechnology, Biology, and Medicine·Bin HuAlicia J El Haj
Jun 26, 2010·Experimental Cell Research·Therese E HolmströmJan Nedergaard
May 23, 2003·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Rie UtohKatsutoshi Yoshizato
Feb 27, 2008·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Hisayuki AmanoYoshimi Takai
Jul 20, 2011·Journal of Cellular Physiology·François BerthodFrançois A Auger
Apr 9, 2010·Chemical Biology & Drug Design·Yuval Blat
May 16, 2000·The Journal of Laboratory and Clinical Medicine·H IwamotoH Nawata
Jun 23, 2004·Cytokine & Growth Factor Reviews·Alexander Levitzki
Jan 12, 1999·Developmental Biology·D GlahnR Nuccitelli
Nov 30, 2000·Chemistry & Biology·S D SeiwertO C Uhlenbeck
Mar 16, 2017·Journal of Cellular Physiology·Yoshiaki YamanakaPeter C Amadio

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.